Jul 3 |
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
|
Jul 3 |
Sanofi, Regeneron win EU label expansion for Dupixent in COPD
|
Jul 3 |
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
|
Jul 2 |
Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
|
Jul 2 |
Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
|
Jul 1 |
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
|
Jun 28 |
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
|
Jun 28 |
Regeneron lymphoma antibody drug endorsed for conditional approval in EU
|
Jun 28 |
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
|
Jun 27 |
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
|